当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2018年, 第18卷, 第1期, 第1-5页
标题:
进展期胃癌治疗药物的选择
DOI:
10.5428/pcar20180101
作者:
1. 李开春1(1.同济大学附属天佑医院肿瘤科 上海 200331 shtumor@163.com)
2. 李平2(2.第二军医大学长海医院消化内科 上海 200433 tianyouliping@163.com)
摘要:
摘要  近年来,胃癌治疗取得很大进展,但其死亡率在癌症中仍居第三位。细胞毒类药物包括氟尿嘧啶类、紫杉类、第三代铂类药物和拓扑异构酶Ⅰ抑制剂在进展期胃癌化疗中应用,提高了病人生活质量,延长了总生存期,但存在生存期较短、药品不良反应等较多的弊端。随着胃癌发生、发展的分子机制逐步被认识,靶向药物曲妥珠单抗、雷莫芦单抗和阿帕替尼已经在临床应用。本文对进展期胃癌的治疗药物选择做一综述。
欢迎阅读《药学服务与研究》!您是该文第 364 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 李开春1,李平2. 进展期胃癌治疗药物的选择[J]. 药学服务与研究. 2018; 18(1): 1-5.
英文著录格式 LI KaiChun1,LI Ping2. Option of drugs for treatment of advanced gastric cancer[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2018; 18(1): 1-5.
参考文献:
1. Torre L A,Bray F,Siegel R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
2. Chen W,Zheng R,Zeng H,et al.Annual report on status of cancer in China,2011[J].Chin J Cancer Res,2015,27(1):2-12.
3. Wagner A D,Grothe W,Haerting J,et al.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data[J].J Clin Oncol,2006,24(18):2903-2909.
4. GASTRIC(Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group,Oba K,Paoletti X,et al.Role of chemotherapy for advanced/recurrent gastric cancer:an individual-patient-data meta-analysis[J].Eur J Cancer,2013,49(7):1565-1577.
5. Bang Y J,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
6. Kim T Y,Oh D Y,Bang Y J.Capecitabine for the treatment of gastric cancer[J].Expert Rev Gastroenterol Hepatol,2015,9(12):1471-1481.
7. Ryu M H,Kang Y K.ML17032 trial:capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer[J].Expert Rev Anticancer Ther,2009,9(12):1745-1751.
8. Okines A F,Norman A R,McCloud P,et al.Meta-analysis of the REAL-2 and ML17032 trials:evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer[J].Ann Oncol,2009,20(9):1529-1534.
9. Chhetri P,Giri A,Shakya S,et al.Current development of anti-cancer drug S-1[J].J Clin Diagn Res,2016,10(11):XE01-XE05.
10. Koizumi W,Narahara H,Hara T,et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer(SPIRITS trial):a phase Ⅲ trial[J].Lancet Oncol,2008,9(3):215-221.
11. Ajani J A,Rodriguez W,Bodoky G,et al.Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:the FLAGS trial[J].J Clin Oncol,2010,28(9):1547-1553.
12. Gadgeel S M,Shields A F,Heilbrun L K,et al.Phase Ⅱ study of paclitaxel and carboplatin in patients with advanced gastric cancer[J].Am J Clin Oncol,2003,26(1):37-41.
13. Hironaka S,Ueda S,Yasui H,et al.Randomized,open-label,phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial[J].J Clin Oncol,2013,31(35):4438-4444.
14. van Cutsem E,Moiseyenko V M,Tjulandin S,et al.Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group[J].J Clin Oncol,2006,24(31):4991-4997.
15. Ajani J A.Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction:evolution of the docetaxel,cisplatin,and 5-fluorouracil regimen[J].Cancer,2008,113(5):945-955.
16. Cunningham D,Starling N,Rao S,et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer[J].N Engl J Med,2008,358(1):36-46.
17. Dank M,Zaluski J,Barone C,et al.Randomized phase Ⅲ study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction[J].Ann Oncol,2008,19(8):1450-1457.
18. Croxtall J D,McKeage K.Trastuzumab:in HER2-positive metastatic gastric cancer[J].Drugs,2010,70(17):2259-2267.
19. Shen L,Xu J M,Feng F Y,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer:a Phase Ⅲ,multi-center,randomized controlled trial,Chinese subreport[J].Chin J Oncol,2013,35(4):295-300.
20. Sawaki A,Ohashi Y,Omuro Y,et al.Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer:a subgroup analysis of the Trastuzumab for Gastric Cancer(ToGA) study[J].Gastric Cancer,2012,15(3):313-322.
21. Poole R M,Vaidya A.Ramucirumab:first global approval[J].Drugs,2014,74(9):1047-1058.
22. Fuchs C S,Tomasek J,Yong C J,et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial[J].Lancet,2014,383(9911):31-39.
23. Wilke H,Muro K,Van Cutsem E,et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW):a double-blind,randomised phase 3 trial[J].Lancet Oncol,2014,15(11):1224-1235.
24. Casak S J,Fashoyin-Aje I,Lemery S J,et al.FDA approval summary:ramucirumab for gastric cancer[J].Clin Cancer Res,2015,21(15):3372-3376.
25. Brower V.Apatinib in treatment of refractory gastric cancer[J].Lancet Oncol,2016,17(4):e137.
26. Li J,Qin S,Xu J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225.
27. Li J,Qin S,Xu J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol,2016,34(13):1448-1454.
28. Li K,Li J.Current molecular targeted therapy in advanced gastric cancer:a comprehensive review of therapeutic mechanism,clinical trials,and practical application[J].Gastroenterol Res Pract,2016,2016(9742):1-9.